Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
JAMA Dermatol, 2022.
Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM; BADBIR Study Group.
Read publication: JAMA Dermatol
Related
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe pso...
Application of information theoretic feature selection and machine learning methods for the developm...
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab a...
0 Comments